BI 60732

BI 60732 is an investigational small molecule drug that acts as a factor Xa inhibitor. It was initially developed by Boehringer Ingelheim (C.H. Boehringer Sohn AG & Co. KG). Factor Xa inhibitors are anticoagulants that work by selectively blocking the activity of factor Xa, a key enzyme in the coagulation cascade, thereby preventing blood clot formation. The primary indication for BI 60732 is likely related to thrombosis or other conditions requiring anticoagulation therapy. As of the latest available information, its global highest R&D status is pending and it has undergone early-phase clinical evaluation for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers[1][2].